Currently, CAR-T immunotherapy targeting IL13Ra2 are being research as the target is a commonly expressed membrane-bound protein in over three-quarters of GBMs and is associated with activating the mTOR (mammalian target of rapamycin) pathway, which favours tumour growth (Thaci et al., 2014; Filley et al., 2017). The gene discussed is MTOR; the disease is neoplasm.